C
Chang Xu
Researcher at University of Sydney
Publications - 467
Citations - 13012
Chang Xu is an academic researcher from University of Sydney. The author has contributed to research in topics: Computer science & Chemistry. The author has an hindex of 42, co-authored 260 publications receiving 7189 citations. Previous affiliations of Chang Xu include University of Melbourne & Information Technology University.
Papers
More filters
Journal ArticleDOI
Event-triggered mechanism based robust fault-tolerant control for networked wind energy conversion system
Zhihong Huo,Chang Xu +1 more
TL;DR: In this article , a robust fault-tolerant control scheme based on event-triggered communication mechanism for a variable-speed wind energy conversion system (WECS) with sensor and actuator failures is proposed.
Journal ArticleDOI
Discovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors.
Yaoguang Huang,Wenwu Liu,Shuoqi Huang,Deping Li,Chang Xu,Xiaowen Jiang,Mingyue Liu,Xin Liu,Cheng Zhu,Limeng Wu,Hua-Shin Chen,Zi-ru Xu,Qing-Chun Zhao +12 more
TL;DR: In this paper , a series of benzofuro[3,2-b]quinoline alkaloid derivatives were used as CDK2 inhibitors through a scaffold hopping strategy.
Journal ArticleDOI
Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips
TL;DR: In this article , a label-free, rapid, and high-throughput technique was developed for separating cancer cells from ascites and peritoneal lavages using an integrated microfluidic device, taking advantage of dean flow fractionation and deterministic lateral displacement.
Proceedings ArticleDOI
Large-Scale Wi-Fi Hotspot Classification via Deep Learning
TL;DR: This work describes the problem of classifying hundreds of millions of Wi-Fi hotspots using only connection and user count characteristics using a combination of deep learning and frequency analysis.
Journal ArticleDOI
Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer.
Limeng Wu,Wenjie Liu,Yaoguang Huang,Chengze Zhu,Qun-Ying Ma,Qiong Wu,Liting Tian,Xiangling Feng,Mingyue Liu,Nianshuang Wang,Xiangbo Xu,Xin Liu,Chang Xu,Jingsong Qiu,Zi-ru Xu,Wenwu Liu,Qing-Chun Zhao +16 more
TL;DR: ZLMT-12 (35) showed the most potent antiproliferative activity (GI50 = 0.006 μM for HCT116) and superior CDK2/9 inhibitory properties as mentioned in this paper .